FDA Inspection 1301370 — Quality CDMO
The FDA completed an inspection of Quality CDMO on February 12, 2026 in Fort Worth, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 12, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Unapproved and Misbranded Drugs
- Location
- Fort Worth, TX (United States)